MARC details
| 000 -LEADER |
|---|
| fixed length control field |
04126ntm a2200301 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
12102116 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20210308140153.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150118s2018 ua a f bm 000 0 eng | |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-EULC |
| Transcribing agency |
EG-EULC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract/overprinted title or subtitle |
ara |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.19 |
| Item number |
F.A.P |
| Edition number |
22 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Fouly, Aya Mohamed Adel Abdel Halim. |
| 245 12 - TITLE STATEMENT |
|---|
| Title |
A pharmaceutical study on certain transdermal delivery systems of an antiemetic drug / |
| Statement of responsibility, etc |
Aya Mohamed Adel AbdelHalim Fouly ; Supervisors Prof. Dr. Hussein Ammar (Professor, chairman of pharmaceutics and pharmaceutical technology department, faculty of pharmaceutical sciences and pharmaceutical industries, Future university in Egypt), Prof. Dr. Magdy Ibrahim (Professor of pharmaceutics and industrial pharmacy, faculty of pharmacy, Cairo university), Prof. Dr. Mina Ibrahim Tadros (Professor of pharmaceutics and industrial pharmacy, vice dean for community services and environment development affairs, faculty of pharmacy, Cairo university) |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
دراسه صيدليه لانظمة توصيل عبر ا لجلد لعقار مضاد للقئ |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2018 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
xi, 251 pages, 7 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
24 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Supervisors Prof. Dr. Hussein Ammar (Professor, chairman of pharmaceutics and pharmaceutical technology department, faculty of pharmaceutical sciences and pharmaceutical industries, Future university in Egypt), Prof. Dr. Magdy Ibrahim (Professor of pharmaceutics and industrial pharmacy, faculty of pharmacy, Cairo university), Prof. Dr. Mina Ibrahim Tadros (Professor of pharmaceutics and industrial pharmacy, vice dean for community services and environment development affairs, faculty of pharmacy, Cairo university) |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (Ph.D.)-Cairo university, Faculty of pharmacy, Department of Pharmaceutics and Industrial pharmacy, 2018. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc |
Cancer treatment is commonly followed by nausea and emesis, namely: Chemotherapy-induced nausea and vomiting (CINV) which may affect the quality of patient life and lead to discontinuance or decreasing the dose of chemotherapy. 5-HT3 receptor antagonists showed superiority over other drugs in the prohibition and curing of CINV, Ondansetron hydrochloride (OND) is a 5-HT3 receptor antagonists commonly used for management of emesis after operations, radiotherapy or even chemotherapy. The oral dose of ondansetron is 8 mg. It is available in number of dosage forms; intravenous or intramuscular injections, tablets, oral solution, orally disintegrating tablets and suppositories. Ondansetron suffers from rapid elimination (tuzi 3-5 h) and low bioavailability (about 60%) as a result of first-pass metabolism effect. Moreover, frequent dosing and invasive dosage forms of ondansetron decrease patient compliance, hence, comes the importance of developing a convenient OND delivery system. Therefore, transdermal delivery may represent a good tool to increase convenience to the patient. Moreover, physicochemical properties of ondansetron HCI (Mw: 365.15; logD (pH5.5): 0.19; logP: 2.07) increase chances for successful transdermal delivery. This work investigated two different approaches for enhancing the transdermal delivery of OND. The first approach was loading OND into bilosomal systems in comparison to niosomes and conducting in-vitro and ex- vivo permeation and confocal laser scanning microscopy (CLSM) studies for evaluation of the best achieved systems. The second one included high frequency ultrasound mediated permeation of OND-loaded bilosomal gel systems at the optimized conditions followed by CLSM studies, The best achieved bilosomal system, bilosomal gel system, and high frequency ultrasound conditions were evaluated for in-vivo histopthological and permeation studies in comparison to commercial OND solution (emerest 2mg/mL.) |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English, abstracts in English and Arabic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmaceutics. |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Thesis |
| Source of classification or shelving scheme |
Dewey Decimal Classification |